J&J Innovative Medicine Saudi Arabia and Gulf’s Post

#Horizon #Europe #health partnerships discussing closer #cooperation: 1. Enhanced Coordination Needed-Representatives emphasized the necessity for greater synergy between the EU’s public-private partnerships and other instruments to effectively translate health research investments into better patient outcomes. 2. Commission's Role in Synergy-The European Commission has been working to increase cooperation across its directorates general, as highlighted by Carmen Laplaza Santos, head of unit for health innovation. 3. Technology Convergence-The intersection of various technologies like biotechnology, nanotechnology, engineering, digitalization, and big data is transforming healthcare, underscoring the need for coordinated efforts. 4. EU4Health Programme-The €5 billion EU4Health programme aims to strengthen Europe’s healthcare systems, covering areas from pandemic preparedness to drug manufacturing. 5. Strategic Research and Innovation Agendas (SRIAs)-Each health partnership updates its SRIA periodically to reflect new research priorities, providing opportunities for knowledge sharing and collaboration. 6. Challenges in Coordination-Ensuring that different partnerships align their activities without duplication remains a complex task, with the burden of coordination largely falling on the Commission. 7. No Joint Calls Yet-While there is readiness to collaborate, launching joint calls across partnerships is not imminent due to the complexity involved. 8. Focus on Different Innovation Stages-Partnerships might focus on different parts of the innovation cycle, with one managing basic research calls and another handling implementation, as suggested by Gerda Geyer of the THCS partnership. 9. Capacity Building and Information Sharing-Training, workshops, and capacity-building initiatives are realistic avenues for collaboration among the partnerships. 10. ERA4Health Working Group-The ERA4Health partnership has set up a working group to identify potential synergies with other EU partnerships and initiatives to avoid overlap in their calls. These takeaways illustrate the ongoing efforts and challenges in aligning various health research initiatives under Horizon Europe to maximize their impact on healthcare systems across Europe

How do we lay the foundations for a thriving biotech sector? Our presentation at this year's Abu Dhabi Global Healthcare Week emphasised the importance of investment across the biotech ecosystem – spanning talent development, education, multi-sector collaboration, infrastructure and appropriate regulatory policies. Explore the takeaways: http://econimpact.co/x4 #biotech #healthcare #adghw

Department of Health Abu Dhabi inks strategic partnership with Masdar City, Xlife Sciences AG, and Thermo Fisher Scientific: The agreement will see all parties supporting innovation within Abu Dhabi's healthcare sector, driving clinical research and clinical trial activities, and developing an ecosystem to support the Emirate's life science start-ups

🔬✨ Transforming Science into Solutions: The Power of Translational Research in Healthcare ✨🔬 In the evolving field of healthcare, translational research stands as a beacon of progress. It's not about advancing scientific knowledge; it's about bridging the gap between cutting-edge discoveries in laboratories and tangible benefits at the patient's bedside. By fostering collaboration between scientists, clinicians, and healthcare providers, we're creating a robust ecosystem where ideas evolve into actionable treatments. Whether it's pioneering personalized medicine approaches, harnessing the potential of biotechnology, or integrating digital health innovations, translational research in the UAE is paving the way for a healthier future. I'm privileged to be part of this transformative journey, where every day brings us closer to turning research into real-world solutions. #TranslationalResearch #HealthcareInnovation #PatientCare #UAEHealthcare #MedicalResearch #InnovativeMedicine #ScientificBreakthroughs #LeaderLeader Biotech Pharma #LeaderLeader Life Sciences #LeaderLeader Healthcare

As the host state for the ‘Biggest week in biotech’ down under, we’re unashamedly spending the week celebrating some of the reasons why we think Victoria is the best place to do biotech. Reason #1: Our thriving sector Victoria's healthtech sector is booming, comprising over 40% of Australia’s listed health technology firms. With significant growth in recent years (40%), it now employs over 100,000 individuals. We have a combined market capitalisation of over $181 billion, and as at 2021, Victoria exported health technology products worth $3.02 billion - our highest-value manufactured export. Victoria's health technology sector has many strengths including: · Supporting infrastructure for neuroscience, cancer, regenerative medicine, infectious diseases, immunology research, ++ · A growing global reputation in advanced manufacturing for pharmaceutical and medical technology products. This includes new capabilities to develop and manufacture mRNA based products. · A growth pad for development of innovation and advanced health technologies that provides access to skilled medical product design and manufacturing capabilities. · An experienced biotechnology investment ecosystem. This ecosystem has proven ability to manage and assist the commercialisation of health technologies. It does this through research into products delivered across global markets. · Proven expertise in healthtech development across many stages of the discovery process. · A cost-effective and rapid regulatory system for high-quality clinical trials. This includes access to leading clinical researchers and ethically-diverse participant recruitment pool. #BMN #TeamVictoria

ASSESS-DHT Project Launch 🚀 We are thrilled to announce the official launch of the ASSESS-DHT project, an initiative aimed at boosting the adoption of trustworthy and effective Digital Health Technologies (DHT) across Europe. As the proud coordinator of this project, empirica is set to lead work packages 1 and 6, playing a pivotal role in shaping the future of digital healthcare. 🌐 Project Overview: ASSESS-DHT is dedicated to creating a more coherent digital single market, enabling health systems and patients to access DHT from all corners of Europe. Our mission involves developing an innovative assessment framework that goes beyond existing models, ensuring uniform Health Technology Assessment (HTA) adoption throughout Europe. This framework will address new assessment challenges in Digital Therapeutics, AI, and telehealth. 🤝 Our Consortium: We are happy to collaborate with a diverse consortium comprising: The ASSESS-DHT consortium comprises 14 partners from 7 countries representing HTA, research organisations, DHT companies, professional and patient organisations as well as intergovernmental and multi-stakeholder associations at EU, Member State and regional level. 🛠️ Our Role: We will be spearheading Work Package 1 - Coordination, communication, and dissemination. Our objectives include co-ordinating the work plan, ensuring smooth collaboration, reporting progress to the EC, managing project governance, and maintaining the quality of deliverables. Additionally, we will lead Work Package 6 - Stakeholder engagement and consultation, sustainability, and the European repository. Under this, we will establish mechanisms for obtaining relevant inputs through consultations and expert groups, seek synergies with other initiatives, and design a platform on DHT assessment methods. Stay tuned for more updates on our journey towards revolutionizing digital healthcare in Europe! 💡#ASSESSDHT #DigitalHealth #HealthTech #Empirica #InnovationInHealthcare The European Institute for Innovation Through Health Data Fundación Progreso y Salud Technische Universität Dresden University of Oxford NICE - National Institute for Health and Care Excellence HTA Austria - Austrian Institute for Health Technology Assessment GmbH (AIHTA) The Dental and Pharmaceutical Benefits Agency, TLV International Diabetes Federation Europe Université libre de Bruxelles Technische Universität Berlin Bettercare HeartKinetics Tech4Care European Observatory on Health Systems and Policies

Healthcare & Life Sciences GCCs in India are evolving, driving research & development, driving business growth, and creating sustainable value. Read this interesting report https://lnkd.in/g-NPX-RB Be ready for the journey Scholavar

Honored to participate in panel convened in Geneva to delve into the current drivers of advanced medical technology (MedTech) innovation and access in least developed countries (LDCs). Experts from various sectors, including governments, industry, academia, NGOs, and donors, discussed leveraging intellectual property and innovation to support LDCs in manufacturing medical devices and diagnostics to meet health needs and boost economies.  Organized by World Intellectual Property Organization – WIPO in collaboration with the United Nations Technology Bank for Least Developed Countries (UNTB) and Medtronic the seminar aimed to strengthen the MedTech sector in LDCs. Key insights from case studies on Bangladesh and Rwanda highlighted challenges and opportunities in establishing sustainable MedTech ecosystems, emphasizing capacity building, regulatory frameworks, and the role of IP in fostering innovation. The seminar also underscored the gaps in medical technology access in LDCs, particularly in diagnostics and treatment for non-communicable diseases, and explored how policies and financing could drive MedTech advancements, facilitating the deployment of life-saving technologies. Emphasizing the importance of improving local innovation ecosystems, the discussion highlighted the necessity for targeted investments in healthcare infrastructure and research and development. Edward Kwakwa,Siddhartha Prakash,Federica Irene Falomi, Trevor Gunn, Neta Glaser,IFC - International Finance Corporation

This powerful Health Tech World article by my colleague Gil Bashe highlights the current and potential value of health innovation to the troubled UK economy. Innovation is, though, at risk because the National Health Service is prioritising the maintenance of outdated models of care delivery over the adoption of innovation. (That is true in the English NHS, by far the largest service, and it's even worse in Wales and Northern Ireland; Scotland is a more mixed picture). If the home nation of a discovery spurns it, how can we expect others to support it? The next few years will be crucial: if vested professional interests can be tamed and sclerotic bureaucracies can be prodded, the UK nations could have the biggest unified patient database in Europe. It could open all sorts of models of shared risk and rigorous tracking of impact. But data integration has been tried and sabotaged before, and it's not clear that even the dynamic Westminster secretary of state can clear the hurdles. The government is moving in the wrong direction on global health. The UK used to lead Europe in meeting the UN target of spending 0.7% of GDP on development assistance. Too much of it went to friendly regimes on fuzzy governance or budget support spending, but a decent chunk went to transformative health spending - think UK support for health system strengthening, Gavi and the Global Fund or Amplify Change (with which I'm involved). Today, the UK is hurtling away from that goal with a further effective cuts announced this week. Ireland and Italy, for example, are going in the right direction. The British abdication of responsibility undermines UK innovation focussed on global health - the article talks about malaria, but there are lots of projects Health innovation will only thrive in a national ecosystem that's designed to nurture it #medtech #healthinnovation #biopharma Julie Adrian Julian Tyndale-Biscoe The Association of the British Pharmaceutical Industry (ABPI) Grethe Petersen The Galien Foundation FINN Partners UK Health

The healthcare sector is quietly transforming into a powerhouse for investors. Today on ASA Insights, Ankita Rai from InvestmentMarkets explores why the healthcare sector is emerging as a prime choice for investors, driven by an ageing population, rising healthcare spending, and breakthroughs in biotechnology and telemedicine. Discover the long-term growth potential and specific investment options available in this dynamic sector 👉 https://lnkd.in/gyan-bkv